blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3621620

EP3621620 - SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  03.06.2022
Database last updated on 12.10.2024
FormerRequest for examination was made
Status updated on  14.02.2020
FormerThe international publication has been made
Status updated on  16.11.2018
Formerunknown
Status updated on  19.05.2018
Most recent event   Tooltip06.07.2024New entry: Additional fee for renewal fee: despatch of communication + time limit 
Applicant(s)For all designated states
Domain Therapeutics
Bioparc
Boulevard Sébastien Brandt
67400 Illkirch Graffenstaden / FR
[2021/21]
Former [2020/12]For all designated states
Mavalon Therapeutics Limited
24 Chiswell Street
London EC1Y 4YX / GB
Inventor(s)01 / BLAYO, Anne-Laure
8 Rue Beethoven
67460 Souffelweyersheim / FR
02 / CATELAIN, Thomas
20 rue des Annelets
75019 Paris / FR
03 / DORANGE, Ismet
Hammarby kaj 48
120 63 Stockholm / SE
04 / GENET, Cédric
7 Place de l'Abbé Buchinger
68240 Kientzheim / FR
05 / MANTEAU, Baptiste
14 Rue Achille Fievez
1474 Ways / BE
06 / MAYER, Stanislas
10 Rue des jardins
67114 Eschau / FR
07 / SCHANN, Stephan
31 Rue des Chaumes
67400 Illkirch / FR
 [2020/12]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[2020/12]
Application number, filing date18722600.614.05.2018
[2020/12]
WO2018EP62409
Priority number, dateEP2017017086512.05.2017         Original published format: EP 17170865
[2020/12]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018206820
Date:15.11.2018
Language:EN
[2018/46]
Type: A1 Application with search report 
No.:EP3621620
Date:18.03.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 15.11.2018 takes the place of the publication of the European patent application.
[2020/12]
Search report(s)International search report - published on:EP15.11.2018
ClassificationIPC:A61K31/4985, A61P25/14, C07D487/04, C07D519/00
[2020/12]
CPC:
A61K31/4985 (EP); C07D471/04 (EP,KR,US); C07D471/14 (EP,KR,US);
A61K31/551 (KR); A61P25/14 (EP); A61P25/16 (KR);
C07D223/18 (US); C07D225/08 (EP); C07D401/04 (EP,KR);
C07D401/10 (US); C07D401/14 (EP,KR,US); C07D487/04 (EP,KR,US);
C07D487/14 (EP,KR,US); C07D495/04 (EP,KR,US); C07D519/00 (EP,KR);
G01N33/6872 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/12]
Extension statesME10.12.2019
TitleGerman:SUBSTITUIERTE HETEROCYCLISCHE VERBINDUNGEN ALS ALLOSTERISCHE MODULATOREN VON METABOTROPEN GLUTAMATREZEPTOREN DER GRUPPE II[2020/12]
English:SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS[2020/12]
French:COMPOSÉS HÉTÉROCYCLIQUES SUBSTITUÉS UTILISÉS COMME MODULATEURS ALLOSTÉRIQUES DE RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE DU GROUPE II[2020/12]
Entry into regional phase10.12.2019National basic fee paid 
10.12.2019Designation fee(s) paid 
10.12.2019Examination fee paid 
Examination procedure10.12.2019Amendment by applicant (claims and/or description)
10.12.2019Examination requested  [2020/12]
10.12.2019Date on which the examining division has become responsible
07.06.2022Despatch of a communication from the examining division (Time limit: M06)
19.12.2022Reply to a communication from the examining division
Fees paidRenewal fee
10.12.2019Renewal fee patent year 03
21.05.2021Renewal fee patent year 04
20.05.2022Renewal fee patent year 05
24.05.2023Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
31.05.202407   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[Y]WO2008021545  (VERTEX PHARMA [US], et al) [Y] 1-33 * claim 1 *;
 [Y]WO2008082887  (ABBOTT LAB [US], et al) [Y] 1-33 * example all; claim 1 *;
 [Y]WO2013192347  (UNIV VANDERBILT [US]) [Y] 1-33 * claim 1 *;
 [XP]WO2017081483  (MAVALON THERAPEUTICS LTD [GB]) [XP] 1-33* the whole document *;
 [XY]  - HONG-JUN WANG ET AL, "Synthesis of benzo[6,7][1,4]diazepino[1,2-b]indazol-7(6H)-ones and benzo[f]pyrazolo[1,5-a][1,4]diazepin-4-ones via CuI/l-proline catalyzed intramolecular N2-arylation", TETRAHEDRON LETTERS, AMSTERDAM, NL, (20150201), vol. 56, no. 8, doi:10.1016/j.tetlet.2015.01.031, ISSN 0040-4039, pages 1030 - 1033, XP055242623 [X] 1,3-7,9-14,19-26,30-33 * compounds 2a-2l.4a-4h * [Y] 2,8,15-18,27-29

DOI:   http://dx.doi.org/10.1016/j.tetlet.2015.01.031
by applicantUS3551414
 US3668232
 US3681343
 US3773919
 US4130716
 US4153799
 EP0036676
 EP0052322
 EP0088046
 DE3218121
 EP0102324
 US4485045
 EP0133988
 EP0142641
 EP0143949
 US4544545
 US4863920
 WO9320695
 US2003017200
 US2006046983
 WO2007092000
 WO2008039520
 JP2008118008
 US2008161292
 WO2009158011
 WO2010132601
 WO2013192347
 WO2014117919
    - MATTSON MP., Neuromolecular Med., (20030000), vol. 3, no. 2, pages 65 - 94
    - STEPHANS SE; YAMAMOTO BK, Synapse, (19940000), vol. 17, no. 3, pages 203 - 9
    - PALUCHA A et al., Pharmacol.Ther., (20070000), vol. 115, no. 1, pages 116 - 47
    - CRYAN JF et al., Eur. J. Neurosc., (20030000), vol. 17, no. 11, pages 2409 - 17
    - CONN PJ et al., Trends Pharmacol. Sci., (20090000), vol. 30, no. 1, pages 25 - 31
    - BRAUNER-OSBORNE H et al., J. Med. Chem., (20000000), vol. 43, no. 14, pages 2609 - 45
    - NICOLETTI F et al., Neuropharmacol., (20110000), vol. 60, no. 7-8, pages 1017 - 41
    - SCHOEPP DD et al., Neuropharmacology, (19990000), vol. 38, no. 10, pages 1431 - 76
    - BRIDGES TM et al., ACS Chem Biol, (20080000), vol. 3, no. 9, pages 530 - 41
    - SWANSON CJ., Nat Rev Drug Discov, (20050000), vol. 4, pages 131 - 44
    - CONN PJ et al., Trends in Pharmacol Sci, (20090000), vol. 30, pages 25 - 31
    - PITSIKAS N; MARKOU A, Neuropharmacology, (20140000), vol. 85, pages 27 - 35
    - ADEWALE AS et al., J Pharmacol Exp Ther, (20060000), vol. 318, pages 922 - 31
    - JONES CK et al., Neuropharmacology, (20050000), vol. 49, no. 1, pages 206 - 18
    - CAULDER EH et al., Epilepsy Res., (20140000), vol. 108, no. 2, pages 171 - 81
    - REINER A et al., Brain Research, (20120000), pages 161 - 72
    - REINER A et al., Neurobiology of disease, (20120000), vol. 47, pages 75 - 91
    - BATTAGLIA G et al., PLoS ONE, (20090000), vol. 4, no. 8, page e6591
    - BATTAGLIA G et al., Neuropharmacology, (20030000), vol. 45, pages 155 - 66
    - BATTAGLIA G et al., Neurobiology of disease, (20150000), vol. 74, pages 126 - 36
    - CORTI C et al., J. Neurosci, (20070000), vol. 27, no. 31, pages 8297 - 308
    - CARACI F. et al., Mol. Pharmacol., (20110000), vol. 79, no. 3, pages 618 - 26
    - VASTAG, B., Nature, (20100000), vol. 466, no. 7309, pages 916 - 8
    - SCHOBER A. et al., Neurobiol Dis, (20060000), vol. 25, no. 2, pages 378 - 91
    - GILL SS., Nat Med, (20030000), vol. 9, no. 5, pages 589 - 95
    - SLEVIN JT., J. Neurosurg., (20050000), vol. 102, pages 216 - 222
    - REVILLA S et al., CNS Neurosci. Ther., (20140000), vol. 20, no. 11, pages 961 - 72
    - PERTUSA M et al., Neurobiology Aging, (20080000), vol. 29, no. 9, pages 1366 - 79
    - EBERT AB et al., Exp. Neurol., (20100000), vol. 224, no. 1, pages 155 - 62
    - TRABANCO AA et al., Curr Med Chem, (20110000), vol. 18, no. 1, pages 47 - 68
    - WANG H et al., Tetrahedron, (20090000), vol. 65, pages 8956 - 8960
    - WANG HJ et al., Tet. Lett., (20110000), vol. 52, pages 541 - 543
    - NORRIS D et al., Tet. Lett., (20010000), vol. 42, pages 4297 - 4299
    - FAIGL F et al., Chirality, (20120000), vol. 24, pages 532 - 542
    - WANG HJ et al., Tet. Lett., (20150000), vol. 56, pages 1030 - 1033
    - MIYASHIRO J et al., Bioorg. Med. Chem. Lett., (20090000), vol. 19, pages 4050 - 4054
    - BERTELLI L et al., // Farmaco, (19980000), vol. 53, pages 305 - 311
    - ANZINI M et al., Med. Chem. Res., (19930000), vol. 3, pages 249 - 256
    - VACHHANI DD et al., Eur. J. Org. Chem., (20130000), vol. 7, pages 1223 - 1227
    - BEAUMONT S et al., Eur. J. Org. Chem., (20080000), vol. 30, pages 5162 - 5175
    - GREAM GE et al., Journal of the Chemical Society D: Chemical Communications, (19700000), vol. 15, pages 895 - 896
    - GSCHWEND HW et al., J. Org. Chem., (19820000), vol. 47, no. 19, pages 3652 - 3657
    - GU X et al., Eur. J. Med. Chem., (20120000), vol. 51, pages 137 - 144
    - HADDEN M et al., Bioorg. Med. Chem. Lett., (20100000), vol. 20, no. 9, pages 2912 - 2915
    - JEFFREY JL et al., Angew. Chem. Int. Ed. Engl., (20130000), vol. 52, no. 8, pages 2194 - 2197
    - KELLER L et al., J. Med. Chem., (20080000), vol. 51, no. 12, pages 3414 - 3421
    - LELEU S et al., Tetrahedron: Asymmetry, (20040000), vol. 15, no. 24, pages 3919 - 3928
    - LIU J et al., J. Org. Chem., (20160000), vol. 81, no. 20, pages 9695 - 9706
    - MOUSTAID K et al., Can. J. Chem., (19920000), vol. 70, no. 3, pages 802 - 808
    - OHNO A et al., J. Am. Chem. Soc., (19940000), vol. 116, no. 18, pages 8133 - 8137
    - OHNO A et al., Bull. Chem. Soc. Jpn., (19960000), vol. 69, no. 6, pages 1679 - 1685
    - OHNO A et al., J. Am. Chem. Soc., (19980000), vol. 120, no. 6, pages 1186 - 1192
    - OHNO A et al., Tetrahedron Letters, (19990000), vol. 40, no. 24, pages 4577 - 4580
    - OHNO A et al., J. Org. Chem., (20000000), vol. 65, no. 20, pages 6381 - 6387
    - OHNO A et al., Tetrahedron Letters, (20010000), vol. 42, no. 3, pages 399 - 401
    - PONS V et al., ACS Med. Chem. Lett., (20110000), vol. 2, no. 8, pages 565 - 570
    - PUTEY A et al., Tetrahedron, (20070000), vol. 63, no. 4, pages 867 - 879
    - PUTEY A et al., J. Med. Chem., (20090000), vol. 52, no. 19, pages 5916 - 5925
    - TAYLOR EC et al., J. Am. Chem. Soc., (19800000), vol. 102, no. 21, pages 6513 - 6519
    - THOMAS HG et al., J. Heterocyclic Chem., (19840000), vol. 21, no. 4, pages 1057 - 1062
    - VASSE JL et al., Tetrahedron Letters, (20010000), vol. 42, no. 28, pages 4613 - 4616
    - VASSE JL et al., Chem. Commun. (Camb)., (20020000), vol. 19, pages 2256 - 2257
    - ATZRODT J et al., Bioorg Med Chem, (20120000), vol. 20, no. 18, pages 5658 - 5667
    - WILLIAM JS et al., Journal of Labelled Compounds and Radiopharmaceuticals, (20100000), vol. 53, no. 11-12, pages 635 - 644
    - MODVIG A et al., J Org Chem, (20140000), vol. 79, pages 5861 - 5868
    - BUNDGAARD, H., Design of Prodrugs, Elsevier, (19850000), pages 7 - 9,21-24
    - Remington's Pharmaceutical Sciences
    - SIDMAN, U. et al., Biopolymers, (19830000), vol. 22, pages 547 - 556
    - R. LANGER et al., J. Biomed. Mater. Res., (19810000), vol. 15, pages 167 - 277
    - R. LANGER, Chem. Tech., (19820000), vol. 12, pages 98 - 105
    - EPSTEIN et al., Proc. Natl. Acad. Sci., (19850000), vol. 82, pages 3688 - 3692
    - HWANG et al., Proc. Natl. Acad. Sci., (19800000), vol. 77, pages 4030 - 4034
    - BRABET I et al., Neuropharmacology, (19980000), vol. 37, no. 8, pages 1043 - 51
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.